NO. 4 THE FORUM, ST. HELIER, Y9
Reports Third Quarter 2025 Financial Results
Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
News
Reports Second Quarter 2025 Financial Results
News, Material Contracts
Investor Presentation
Earnings Release
Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
S-8 POS